Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DSM and DecImmune Therapeutics Sign Agreement

Published: Monday, April 22, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
Agreement to develop N2 pathway blocking antibody.

DSM Pharmaceutical Products has announced that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.

The agreement covers the initiation of development activities by DSM for DecImmune's lead monoclonal antibody program.

The initial development will be performed at DSM Biologics' Groningen, the Netherlands, facility, with the objective of progressing manufacture of clinical trial material to DSM's facility in Brisbane, Australia.

DecImmune's proprietary antibody therapeutic is designed to reduce tissue damage and improve ventricular function associated with myocardial infarction.

Regaining full function after a heart attack can be complicated by irreversible tissue damage and scar formation that leads to a significant loss in cardiac pumping efficiency.

In a range of experimental models, DecImmune has shown that it is possible to reduce damage to heart tissue by using their proprietary therapeutic antibody.

In these models the reduction in damage to heart tissue results in pumping efficiency returning to normal levels. DecImmune is also investigating this targeted approach to reduce tissue damage for a range of other acute and chronic post-injury settings.

Karen King, President of DSM Biologics, commented “We are delighted to be working with DecImmune on their exciting project. DSM is committed to delivering our clients around the world the highest quality solutions and services.”

DSM Biologics, a business unit of DSM Pharmaceutical Products, focuses on optimizing mammalian-based biopharmaceutical manufacturing through its unique set of technologies and expertise.

In addition to an R&D and manufacturing site in Groningen, the Netherlands, DSM is starting up operations in 2013 in Brisbane, Australia, with the support of the Government of Queensland and the Commonwealth of Australia.

The Brisbane facility is DSM's prototype 'biologics plant of the future' for the production of biopharmaceuticals employing DSM's proprietary technologies.

DSM's technologies drive down cost, processing times, scale-up risk and capital requirements to meet market demand for developing cost-effective, lifesaving medications.

"Partnering with DSM for its antibody process development and manufacturing enables DecImmune to move rapidly through late preclinical studies and into clinical development. DSM's experience, capacity, and technical expertise in Groningen and Brisbane meet the full range of DecImmune's manufacturing needs. We look forward to working with one of the world's leading science-based companies as our manufacturing partner," stated Christopher K. Mirabelli, Ph.D., President and CEO of DecImmune and Managing Director at HealthCare Ventures, DecImmune's lead investor.

"In line with DSM's stated strategy, and fulfillment of its commitment to bring manufacturing and technological excellence to the global biopharmaceutical market, this agreement with DecImmune represents the best of what DSM is doing to help our customers serve critical needs in healthcare. The combination of the Groningen and Brisbane operations will support DecImmune throughout the development process and on to clinical trials." declared Alexander Wessels, President and CEO of DSM Pharmaceutical Products.

David Hughes, CEO of BioPharmaceuticals Australia (BPA), said "We have always been of the view that success for this facility would come from leveraging both local and global demand. BPA’s ongoing partnership with DSM brings a wealth of expertise to the region. Brisbane is home to sophisticated biomanufacturing technology and this contract with DecImmune bolsters the city as an internationally-recognized location for biotherapeutic development."

BPA, an industry-development company owned by the Queensland State Government, put together the partnering deal with DSM Biologics, and is currently project managing the final stages of the construction of the new facility in cooperation with DSM Biologics.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DSM and Opthea Sign Agreement
Agreement to manufacture Opthea’s lead product for eye disease.
Wednesday, October 30, 2013
DSM Celebrates Opening of New cGMP Facility
DSM Pharmaceutical Products officially opens its new cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia.
Wednesday, October 30, 2013
DSM Announces Biologics Development and Manufacturing Agreement for Australian Facility
DSM has signed a biologics contract manufacturing agreement with Paranta Biosciences.
Thursday, October 25, 2012
DSM Announces South American Biologics Contract Manufacturing Agreement
DSM sign contract manufacturing agreement with RECEPTA Biopharma.
Tuesday, July 17, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!